Focus:
AI
-
29 April 2020 Analysis
Covid-19 pandemic: how modelling can support drug development
Central to the fight against Covid-19 is the clinical development of drugs, including novel compounds and those already approved for other indications. One way to support these efforts is through...
-
22 April 2020 News
Real-world evidence the most impactful emerging technology in COVID-19 management: Poll
New-age emerging technologies are projected to have a significant impact on managing the coronavirus pandemic (COVID-19). Verdict has conducted a poll to assess which emerging technology among artificial intelligence (AI),...
-
2 April 2020 News
ImmunityBio and Microsoft create 3D model to support Covid-19 research
Immunotherapy company ImmunityBio has partnered with Microsoft to leverage the latter’s Azure platform to create a 3D model of Covid-19’s spike protein.
-
1 April 2020 News
Exscientia forms UK-US partnership to screen possible Covid-19 drugs
Artificial intelligence (AI) drug discovery company Exscientia has expanded its ongoing anti-viral drugs partnership with the UK’s national synchrotron facility Diamond Light Source and University of Oxford across the Atlantic...
-
31 March 2020 Analysis
IQVIA Q&A: do the benefits of AI outweigh ethical concerns?
AI has revolutionised healthcare by drastically reducing the time it takes to develop and commercialise a drug. Allie Nawrat talks to IQVIA’s technology solutions practice leader Updesh Dosanjh about the...
-
25 March 2020 Analysis
Turning pharma green: an eco-wish list for the industry
The reality of climate change is hard to ignore. As one of the biggest polluters, and simultaneously the industry tasked with trying to tackle the global health outcomes of environmental...
-
20 March 2020 pressreleases
How AI Is Refining the Pharma Supply Chain
Artificial intelligence (AI) is guaranteed to renovate the pharmaceutical cold chain; not in the distant, proposed future, but in the following several years.
-
3 February 2020 Analysis
Life sciences in 2030: predicting the future with the Pistoia Alliance
How will life sciences and healthcare have advanced by 2030? The Pistoia Alliance has published a report suggesting possible answers to this question, thereby helping companies and organisations decide where...
-
12 December 2019
Almirall signs deal for Iktos’ AI technology in drug design
Spanish pharmaceutical firm Almirall has agreed with Iktos to leverage the latter’s generative modelling artificial intelligence (AI) technology to design novel drugs.
-
11 December 2019 News
Flagship Pioneering launches Cellarity for cell behaviour drugs
Flagship Pioneering has launched a new company, Cellarity, to discover drugs based on insights from research of cellular behaviours.